TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21194606
Drug: 150-mg reference
Normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150-mg reference formulation of 25-desacetyl rifampicin
Study: 10197802
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin (AmBisome) 2 mg/kg three times weekly
Study: 7556234
Drug: Norfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (200 mg/day)
Study: 26095068
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product containing probiotic (FMPP) 65 mL/day for 6 weeks
Study: 26095068
Drug: Open-label FMPP
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label FMPP treatment
Study: 26095068
Drug: Withdrawal phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Withdrawal phase after open-label FMPP treatment
Study: 24285428
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 360 µg thrice weekly for 8 weeks
Study: 24285428
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 720 µg thrice weekly for 8 weeks
Study: 24285428
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 1080 µg thrice weekly for 8 weeks
Study: 22211999
Drug: PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA therapy for 12 months
Study: 19384844
Drug: Mineral metabolism
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral metabolism control
Study: 10417626
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream containing sonicated Streptococcus thermophilus
Study: 10417626
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream containing purified bacterial neutral sphingomyelinase
Study: 8625149
Drug: Sandostatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandostatin (1 mg every 8 hours for 14 days)
Study: 27802556
Drug: Osteopathic Cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Cranial Manipulative Medicine (OCMM)
Study: 27802556
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (light pressure applied to the cranium)
Study: 24853043
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus NCFM alone for 21 days at a total dose of 2 × 10(10) CFU b.d.
Study: 24853043
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus NCFM in combination with B-LBi07 for 21 days at a total dose of 2 × 10(10) CFU b.d.
Study: 24853043
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (L-NCFM alone and L-NCFM with B-LBi07)
Study: 18977159
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release hydromorphone
Study: 17210048
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick test (SPT) reactivity to Ara h 2 at low concentration (0.1 micro g/mL)
Study: 17210048
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick test (SPT) reactivity to Ara h 6 at low concentration (0.1 micro g/mL)
Study: 17210048
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick test (SPT) reactivity to Ara h 1 at high concentration (100 micro g/mL)
Study: 17210048
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick test (SPT) reactivity to Ara h 3 at high concentration (100 micro g/mL)
Study: 17210048
Drug: Eliciting dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliciting dose (ED)
Study: 15097240
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 or 50 mg daily)
Study: 12470179
Drug: Levetiracetam (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (3000 mg)
Study: 11289465
Drug: Behavioral-Family Systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral-Family Systems Therapy (BFST)
Study: 10826241
Drug: Current Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current Therapy (CT)
Study: 9286892
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous epinephrine-containing test dose
Study: 9286892
Drug: No premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No premedication followed by intravenous test dose containing 3 ml of 1.5% lidocaine + 15 microg epinephrine
Study: 9286892
Drug: No premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No premedication followed by intravenous saline 3 ml
Study: 9286892
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (5 microg/kg 1.5 h before hemodynamic determinations) followed by intravenous saline
Study: 7900069
Drug: BAY U3405
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY U3405 (20 mg four times a day from day 1 to day 3)
Study: 1993628
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (60.0 Gy)
Study: 1993628
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (50.0 Gy)
Study: 1993628
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (60.0 Gy) in supraglottic larynx patients
Study: 1993628
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (50.0 Gy) in supraglottic larynx patients
Study: 31350916
Drug: Haloperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2.5 mg intravenously three times daily, maximum 20 mg daily)
Study: 8437833
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment
Study: 26915028
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser treatment
Study: 25623461
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment in PCOS patients (Group B)
Study: 25623461
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment in PCOS patients (Group A)
Study: 17123696
Drug: PCOS patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOS patients with insulin resistance
Study: 15282204
Drug: Autoadjusted CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoadjusted CPAP titration
Study: 15282204
Drug: Predicted formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted formula titration with domiciliary adjustment
Study: 15282204
Drug: Standard CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CPAP titration (polysomnography)
Study: 12221219
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of [(13)C(5)]pABG (376 nmol or 100 micro g) in 40 mL apple juice
Study: 12221219
Drug: [(13)C(5)]pABG administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(13)C(5)]pABG administered
Study: 12221219
Drug: Folate intake
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate intake (450 or 850 micro g/d)
Study: 7796721
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy and dispensing of AZT for eight weeks
Study: 7796721
Drug: Supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised therapy and dispensing of AZT
Study: 2192018
Drug: PZQ 50
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ 50 mg/kg per day for 15 days
Study: 2192018
Drug: PZQ 50
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ 50 mg/kg per day for 8 days
Study: 2192018
Drug: ALB 15
Normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALB 15 mg/kg per day for 30 days
Study: 2192018
Drug: ALB 15
Normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALB 15 mg/kg per day for 8 days
Study: 116273
Drug: Scopolamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (5 microgram/kg administered IV)
Study: 30003521
Drug: Oral maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral maternal vitamin B12 supplementation
Study: 21507527
Drug: 1+1 hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1+1 hydromorphone protocol (1 mg IV followed by 1 mg IV after 15 minutes if needed)
Study: 21507527
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (any intravenous opioid at physician's discretion)
Study: 19142106
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75 mg/d
Study: 17381399
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin (TOBI)
Study: 17381399
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin (TOBRA)
Study: 15133405
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR 80 mg/d
Study: 15133405
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR 120 mg/d
Study: 15133405
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR 160 mg/d
Study: 15133405
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR 640 mg/d
Study: 8745663
Drug: Cibenzoline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130 mg twice a day)
Study: 8745663
Drug: Hydroquinidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinidine (300 mg twice a day)
Study: 2762688
Drug: Clonidine (0.25‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.25‐0.3 mg)
Study: 12431829
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (vinorelbine or gemcitabine)
Study: 2664522
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily during the third trimester)
Study: 27989394
Drug: Combined functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined functional voice therapy (10-15 individual sessions, 30-40 minutes each)
Study: 21531412
Drug: Stents in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stents in combination with UDCA and terpene (group B)
Study: 16307723
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (15 mmol L(‐1) solution dripped onto enamel blocks eight times per day)
Study: 12754275
Drug: Bezafibrate treatment
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate treatment for 6 weeks
Study: 8933117
Drug: VA-fortified margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA-fortified margarine (250 g per week providing 28.8 micrograms retinol equivalents per gram)
Study: 12588812
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection therapy
Study: 10235449
Drug: Aspirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1000 mg po)
Study: 2156945
Drug: Topical high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-dose interferon-alpha (10(6) IU/g with 1% nonoxynol-9 in 3.5% methylcellulose) applied three times daily for 5 days
Study: 2156945
Drug: Topical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical low-dose interferon-alpha (10(3) IU/g with 0.1% nonoxynol-9 in 3.5% methylcellulose) applied three times daily for 5 days
Study: 2156945
Drug: Placebo (3.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.5% methylcellulose, alone) applied three times daily for 5 days
Study: 2156945
Drug: Topical high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical high-dose interferon-alpha
Study: 396086
Drug: Labetalol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 150 mg/day
Study: 396086
Drug: Labetalol 300
Normalized name: labetalol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 300 mg/day
Study: 396086
Drug: Labetalol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 600 mg/day
Study: 396086
Drug: Labetalol 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 900 mg/day
Study: 396086
Drug: Labetalol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (all doses)
Study: 31079189
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination therapy (tamsulosin-dutasteride)
Study: 31079189
Drug: Delayed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed combination therapy (switching from tamsulosin monotherapy after 6 months)
Study: 31079189
Drug: Delayed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed combination therapy (switching from tamsulosin monotherapy after 12 months)
Study: 31079189
Drug: Delayed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed combination therapy (switching from tamsulosin monotherapy after 24 months)
Study: 30428445
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for panic disorder with agoraphobia (PD/AG)
Study: 26494524
Drug: Prolonged-release oxycodone-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone-naloxone (OXN PR) 5 mg oxycodone and 25 mg naloxone, twice daily for 16 weeks
Study: 26494524
Drug: Prolonged-release oxycodone-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone-naloxone (OXN PR)
Study: 24364618
Drug: Nicotine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.6 mg)
Study: 24364618
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (male: 0.3g/kg; female: 0.27g/kg)
Study: 24364618
Drug: Nicotine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.6 mg) and Low-dose alcohol (male: 0.3g/kg; female: 0.27g/kg)
Study: 19737321
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy with far-infrared rays at 40 degrees C for 15 minutes once a day on two days a week for a total of 18 sessions
Study: 19737321
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a plain adhesive patch placed on the same acupoint
Study: 16670409
Drug: Naltrexone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone plus medical management (100 mg/d)
Study: 16670409
Drug: CBI without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBI without pills or medical management
Study: 15543092
Drug: PSA testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA testing as a serum tumor marker for early detection and monitoring of treatment response.
Study: 15543092
Drug: Agents such
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents such as selenium and vitamin E in chemoprevention trials.
Study: 23553478
Drug: Carbidopa (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (average daily dose of 480 mg, range 325-600 mg/day)
Study: 21180676
Drug: Milk supplemented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplemented with Lactobacillus rhamnosus LB21 (107 CFU/ml)
Study: 18202961
Drug: EP +
Normalized name: Ashwagandha Extract/Lemon Balm/Melatonin/Theanine, L- 125 MG-3 MG-6 MG-200 MG Oral Capsule [SLEEP + CALM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP + A (n = 31): CEE 0.625 mg plus MPA 2.5 mg and methyltestosterone 2.0 mg
Study: 18202961
Drug: EP (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP (n = 29): CEE 0.625 mg plus MPA 2.5 mg and placebo
Study: 16395548
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid (ASA)
Study: 16395548
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control group (no medication)
Study: 10810433
Drug: CAF adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF adjuvant chemotherapy
Study: 6506819
Drug: Interval run
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interval run exercise therapy for untreated patients
Study: 6506819
Drug: Interval run
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interval run exercise therapy for propranolol-treated patients
Study: 26278704
Drug: Automated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated group (Group 1) using target-controlled infusion system (Veryark‐CLMRIS‐I‐China)
Study: 17937851
Drug: Forlax (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forlax (20 g/d)
Study: 17937851
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 mL/d)
Study: 14693984
Drug: Active Anodyne
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Anodyne Therapy System (ATS) treatment
Study: 9689294
Drug: Protective creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective creams (3 different creams)
Study: 9689294
Drug: Protective creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective creams (1 product)
Study: 2570700
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg diprafenone
Study: 28213365
Drug: TAS-102 35
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 35 mg/m2 orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28‐day cycle (n = 534)
Study: 12897995
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine (10 micro g/kg per hour)
Study: 12897995
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (30 micro g/kg per 3 hours)
Study: 12897995
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine and Intermittent morphine
Study: 10736078
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg.kg‐1 bolus i.v. with an infusion of 3 microg.kg‐1.h‐1
Study: 8932966
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy with eye movement
Study: 8932966
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy without eye movement (eyes-fixed)
Study: 1416894
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 400 mg orally per day for 10 days
Study: 1416894
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg orally per day for 10 days
Study: 3927068
Drug: Ventilation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation group (10 breaths/min with 100% oxygen at a tidal volume of 10 ml/kg)
Study: 17506001
Drug: Imipenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 0.5 g x 3 for 5-7 days
Study: 12131234
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living intervention
Study: 12131234
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of activities of daily living and psychosocial activity intervention
Study: 28580579
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg FI
Study: 28580579
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg RAN
Study: 24909549
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) on RT days 1, 22, and 43 (Arm A)
Study: 24909549
Drug: Cisplatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (20 mg/m(2)/day) and 5-fluorouracil (5-FU; 1000 mg/m(2)/day) continuous 96-hour infusions on RT weeks 1 and 4 (Arm B)